Jung Hun Oh

Dr. Jung Hun Oh

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
JSJoen Sveistrup
Joen Sveistrup
PRPer Munck Af Rosenschöld
Per Munck Af Rosenschöld
JDJoseph O Deasy
Joseph O Deasy
Jung Hun OhJung Hun Oh
Jung Hun Oh
TPTobias Pommer
Tobias Pommer
SESvend Aage Engelholm
Svend Aage Engelholm
Image-guided radiotherapy (IGRT) facilitates the delivery of a very precise radiation dose. In this study we compare the toxicity and biochemical progression-free survival between patients treated with daily image-guided intensity-modulated radiotherapy (IG-IMRT) and 3D conformal radiotherapy (3DCRT) without daily image guidance for high risk prostate cancer (PCa).

1 May 2018 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
SLSangkyu Lee
Sangkyu Lee
SKSarah Kerns
Sarah Kerns
HOHarry Ostrer
Harry Ostrer
BRBarry Rosenstein
Barry Rosenstein
JDJoseph O. Deasy
Joseph O. Deasy
Jung Hun OhJung Hun Oh
Jung Hun Oh

23 December 2019 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
JHJie Hao
Jie Hao
YKYoungsoon Kim
Youngsoon Kim
TMTejaswini Mallavarapu
Tejaswini Mallavarapu
Jung Hun OhJung Hun Oh
Jung Hun Oh
MKMingon Kang
Mingon Kang
Background: Understanding the complex biological mechanisms of cancer patient survival using genomic and clinical data is vital, not only to develop new treatments for patients, but also to improve survival prediction. However, highly nonlinear and high-dimension, low-sample size (HDLSS) data cause computational challenges to applying conventional survival analysis. Results: We propose a novel biologically interpretable pathway-based sparse deep neural network, named Cox-PASNet, which integrates high-dimensional gene expression data and clinical data on a simple neural network architecture for survival analysis. Cox-PASNet is biologically interpretable where nodes in the neural network correspond to biological genes and pathways, while capturing the nonlinear and hierarchical effects of biological pathways associated with cancer patient survival. We also propose a heuristic optimization solution to train Cox-PASNet with HDLSS data. Cox-PASNet was intensively evaluated by comparing the predictive performance of current state-of-the-art methods on glioblastoma multiforme (GBM) and ovarian serous cystadenocarcinoma (OV) cancer. In the experiments, Cox-PASNet showed out-performance, compared to the benchmarking methods. Moreover, the neural network architecture of Cox-PASNet was biologically interpreted, and several significant prognostic factors of genes and biological pathways were identified. Conclusions: Cox-PASNet models biological mechanisms in the neural network by incorporating biological pathway databases and sparse coding. The neural network of Cox-PASNet can identify nonlinear and hierarchical associations of genomic and clinical data to cancer patient survival. The open-source code of Cox-PASNet in PyTorch implemented for training, evaluation, and model interpretation is available at: https://github.com/DataX-JieHao/Cox-PASNet.

1 July 2021 in Bioinformatics
Verified
Journal Article
Open access
PDF file
Jung Hun OhJung Hun Oh
Jung Hun Oh
WCWookjin Choi
Wookjin Choi
EKEuiseong Ko
Euiseong Ko
MKMingon Kang
Mingon Kang
ATAllen Tannenbaum
Allen Tannenbaum
JDJoseph O Deasy
Joseph O Deasy
Convolutional neural networks (CNNs) have achieved great success in the areas of image processing and computer vision, handling grid-structured inputs and efficiently capturing local dependencies through multiple levels of abstraction. However, a lack of interpretability remains a key barrier to the adoption of deep neural networks, particularly in predictive modeling of disease outcomes. Moreover, because biological array data are generally represented in a non-grid structured format, CNNs cannot be applied directly. To address these issues, we propose a novel method, called PathCNN, that constructs an interpretable CNN model on integrated multi-omics data using a newly defined pathway image. PathCNN showed promising predictive performance in differentiating between long-term survival (LTS) and non-LTS when applied to glioblastoma multiforme (GBM). The adoption of a visualization tool coupled with statistical analysis enabled the identification of plausible pathways associated with survival in GBM. In summary, PathCNN demonstrates that CNNs can be effectively applied to multi-omics data in an interpretable manner, resulting in promising predictive power while identifying key biological correlates of disease. The source code is freely available at: https://github.com/mskspi/PathCNN.

12 June 2017 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
MFMichael R Folkert
Michael R Folkert
JSJeremy Setton
Jeremy Setton
AAAditya P Apte
Aditya P Apte
MGMilan Grkovski
Milan Grkovski
RYRobert J Young
Robert J Young
Jung Hun OhJung Hun Oh
Jung Hun Oh
In this study, we investigate the use of imaging feature-based outcomes research (‘radiomics’) combined with machine learning techniques to develop robust predictive models for the risk of all-cause mortality (ACM), local failure (LF), and distant metastasis (DM) following definitive chemoradiation therapy (CRT). One hundred seventy four patients with stage III–IV oropharyngeal cancer (OC) treated at our institution with CRT with retrievable pre- and post-treatment 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scans were identified. From pre-treatment PET scans, 24 representative imaging features of FDG-avid disease regions were extracted. Using machine learning-based feature selection methods, multiparameter logistic regression models were built incorporating clinical factors and imaging features. All model building methods were tested by cross validation to avoid overfitting, and final outcome models were validated on an independent dataset from a collaborating institution. Multiparameter models were statistically significant on 5 fold cross validation with the area under the receiver operating characteristic curve (AUC) = 0.65 ( p = 0.004), 0.73 ( p = 0.026), and 0.66 ( p = 0.015) for ACM, LF, and DM, respectively. The model for LF retained significance on the independent validation cohort with AUC = 0.68 ( p = 0.029) whereas the models for ACM and DM did not reach statistical significance, but resulted in comparable predictive power to the 5 fold cross validation with AUC = 0.60 ( p = 0.092) and 0.65 ( p = 0.062), respectively. In the largest study of its kind to date, predictive features including increasing metabolic tumor volume, increasing image heterogeneity, and increasing tumor surface irregularity significantly correlated to mortality, LF, and DM on 5 fold cross validation in a relatively uniform single-institution cohort. The LF model also retained significance in an independent population.

1 October 2014 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
TYT. Jonathan Yang
T. Jonathan Yang
Jung Hun OhJung Hun Oh
Jung Hun Oh
AAAditya Apte
Aditya Apte
CSChristina H. Son
Christina H. Son
JDJoseph O. Deasy
Joseph O. Deasy
KGKaryn A. Goodman
Karyn A. Goodman